Biotech Offering Significant Return Potential Advances Lead Breast Cancer Trials
Source: Streetwise Reports��(8/18/21)
An H.C. Wainwright & Co. report noted Oncolytics Biotech's overall pelareorep program is on track with several near-term catalysts expected. More >

Global Specialty Pharma Co. Strongly Beats on Consensus Q2 Revenue and Earnings Estimates
Source: Streetwise Reports��(8/18/21)
Paradigm Capital Inc. stated in a research report that Knight Therapeutics Inc. posted significantly better than expected operating and financial results in Q2/21 that greatly exceeded analysts' estimates. Meanwhile, insiders continue to add to their positions, and the company has filed a new NCIB allowing it to purchase up to 10% of the float during the next 12 months. More >

Platform Therapeutics Co. Posts Positive Revenue Surprise in Q2 on Higher Dermatology Product Sales
Source: Streetwise Reports��(8/18/21)
Dawson James Securities Inc. stated in a research update that Fortress Biotech Inc.'s dermatology business shows good growth potential and helped drive a positive revenue surprise in Q2/21. Dawson James has a "Buy" rating on the stock but noted that the real opportunity for the company lies with its vast pipeline and partnerships, which offer real upside potential. More >

Diagnostics Firm Readies for Pivotal FDA Study of Device That Detects Bacterial Lung Infections
Source: Streetwise Reports��(8/18/21)
Promising early results and a new line of equity support Avisa Diagnostic’s drive for IDE approval of its rapid-response breath test for pneumonia, TB, CF, and other lung ailments. More >

Cannabis Products Retailer Achieves Record Sales in Q3 FY21
Source: Streetwise Reports��(8/17/21)
Gross sales of Stem Holdings dba Driven by Stem during the quarter were 104% higher than they were a year ago. More >

Travere Posts Positive Topline Data in Phase 3 IgA Nephropathy Study, Shares Trade Higher
Source: Streetwise Reports��(8/16/21)
Travere Therapeutics shares traded 14% higher after the company reported positive interim results from its ongoing Phase 3 PROTECT study of sparsentan in treating IgA nephropathy, a chronic kidney disease that can lead to end-stage renal disease. More >

Clover Health Shares Grow 12% after Posting Q2 Earnings and 229% Platform User Growth
Source: Streetwise Reports��(8/12/21)
Shares of Clover Health Investments Corp. traded higher after the company reported Q2/21 financial results that included a 140% increase in YoY revenue. More >

Coverage Initiated on Developer of Treatment for Myelofibrosis, GvHD, COVID-19
Source: Streetwise Reports��(8/11/21)
A BTIG report noted that CTI Biopharma's Pacritinib "has the potential to be a lead therapeutic in the myelofibrosis space and in additional indications that could provide material value to CTI and CTI's shares over time." More >

U.S. Cannabis Sector to Show 'Secular Growth With Margin Improvements,' Analyst Says
Source: Streetwise Reports��(8/11/21)
Behind that forecast, in part, are positive cannabis legislative developments and increasing consumer cannabis use, which are covered in a ROTH Capital Partners report. More >

Liquid Avatar Unveils New App to Confirm COVID-19 Testing Status, Reduce New Outbreaks of the Pandemic
Source: Streetwise Reports��(8/11/21)
The Liquid Avatar Credential Ecosystem, or LAVCE, is designed to carry a secure, digital record of a person’s verifiable COVID-19 testing credentials, and future healthcare applications of the technology are expected. More >

Pharma Developer Licenses Patent for Treating Neuroendocrine Cancers from US Ivy League College
Source: Streetwise Reports��(8/10/21)
Algernon Pharmaceuticals reported its acquisition of the exclusive rights from Dartmouth College for a method of use patent for use in treatment of neuroendocrine cancers expressing functional NMDA receptors. More >

Fulcrum Shares Soar on Positive Interim Data in Phase 1 Sickle Cell Disease Study
Source: Streetwise Reports��(8/10/21)
Fulcrum Therapeutics shares rose 125% and set a new 52-week high after the company reported Q2/21 financial results and released positive interim results from its Phase 1 sickle cell disease trial. More >

Cortexyme Expects to Release Positive Topline Data from Ph. 2/3 Alzheimer's Trial by Late Autumn
Source: Streetwise Reports��(8/9/21)
Shares of Cortexyme Inc. traded 47% higher to a new 52-week high after the company reported Q2/21 financial results and provided an update regarding its ongoing Alzheimer's and periodontal disease clinical trials. More >

STAAR Shares Burst Higher after Firm Posts 77% Increase in Q2 Net Sales and Raises FY Outlook
Source: Streetwise Reports��(8/6/21)
Shares of STAAR Surgical Co. traded 20% higher after the company reported Q2/21 financial results highlighting a 93% YoY increase in net sales of its Implantable Collamer® Lenses. More >

US-Based Biopharma 'In Full Reset Mode,' Analyst Says
Source: Streetwise Reports��(8/4/21)
An H.C. Wainwright & Co. report notes that Agios Pharmaceuticals "is rapidly rebooting and has made critical progress on various fronts." More >

Biopharma Makes 'Solid Clinical Progress' in Q2/21
Source: Streetwise Reports��(8/4/21)
The highlights of Oryzon Genomics' Q2/21 clinical advancements were recapped in a Roth Capital Partners report. More >

Novavax Shares Get a Boost as EC Orders up to 200 Million Doses of Its COVID-19 Vaccine
Source: Streetwise Reports��(8/4/21)
Novavax Inc. shares traded nearly 19% higher after the company reported the finalization of an advance purchase agreement with the European Commission to provide up to 200 million doses of its COVID-19 Vaccine. More >

Translate Bio Shares Rise 29% on Sanofi's $3.2 Billion Buyout Bid
Source: Streetwise Reports��(8/3/21)
Shares of Translate Bio Inc. soared to a new 52-week high after the company reported it agreed to be acquired by its collaborative partner Sanofi SA for $38 per share in cash in a deal valued at $3.2 billion. More >

Gene Editing May Terminate Virus Transmission, Combat Heart and Brain Disease With a Single Shot
Source: McAlinden Research for Streetwise Reports��(8/2/21)
McAlinden Research Partners explores the acceleration of gene-editing technology and notes the market is poised to expand as the World Health Organization (WHO) creates new standards for companies to follow. More >

Annovis Shares Rise on Positive Phase 2 Alzheimer's and Parkinson's Disease Trial Results
Source: Streetwise Reports��(8/2/21)
Shares of Annovis Bio Inc. traded 20% higher after the company reported positive interim data from its Phase 2 clinical studies of ANVS401 (Posiphen) for treatment of Alzheimer's and Parkinson's diseases. More >

Sorrento Therapeutics Proceeds with COVID-19 Drug Treatment Trial
Source: Streetwise Reports��(7/28/21)
The latest developments concerning Sorrento Therapeutics, its product portfolio and partners are summarized in a Dawson James Securities report. More >

Biopharma Creates New Business Unit Ahead of Commercial Product Launch
Source: Streetwise Reports��(7/28/21)
The purpose of HTG Molecular Diagnostics' new therapeutics division and early interest in the biopharma's commercial-ready Transcriptome Panel are covered in an H.C. Wainwright & Co. report. More >

Rritual Superfoods at Full-Throttle, Adding CVS, Amazon Along the US Distribution Superhighway
Source: Knox Henderson for Streetwise Reports��(7/28/21)
Knox Henderson takes a close look at Rritual Superfoods and its plans to ramp up mass distribution. More >

Tilray Shares Fly High on Strong Q4 and FY Revenue Growth
Source: Streetwise Reports��(7/28/21)
Shares of Tilray Inc. traded 25% higher after the company reported FY/21 financial results that included a 27% YoY increase in net revenues to $513.1 million driven by a 55% growth in cannabis revenue following its Aphria acquisition. More >

Cannabis Market Delivering for Consumers and Investors
Source: Streetwise Reports��(7/21/21)
As legalization takes hold across the U.S., opportunities for the next generation of cannabis companies expand. Adrian Morante of K2 & Associates finds “trustworthy, capable and reputable” companies with value. More >